cos Telephone consultations - no cost savings, but increased GP workload By feeds.bmj.com Published On :: Thu, 28 Sep 2017 15:02:02 +0000 If you're a patient in the UK, increasingly, your first interaction with the healthcare system won't be the traditional face to fact chat with your doctor - instead you'll have a telephone consultation. The prevalence of these telephone consultations is increasing, and being promoted by CCGs and private companies who administer them - usually as... Full Article
cos Don't save on transport at the cost of the NHS By feeds.bmj.com Published On :: Mon, 24 Sep 2018 10:49:38 +0000 Last week we heard about how evidence in policy making is imperilled - but today we’re hearing about a plan to make evidence about health central to all aspects of government. Laura Webber, director of public health modelling at the UK Health Forum, Susie Morrow, chair of the Wandsworth Living Streets Group and Brian Ferguson, chief economist at... Full Article
cos Glucose-Induced Reactive Oxygen Species Cause Apoptosis of Podocytes and Podocyte Depletion at the Onset of Diabetic Nephropathy By diabetes.diabetesjournals.org Published On :: 2006-01-01 Katalin SusztakJan 1, 2006; 55:225-233Complications Full Article
cos A Lesson in Metabolic Regulation Inspired by the Glucokinase Glucose Sensor Paradigm By diabetes.diabetesjournals.org Published On :: 1996-02-01 Franz M MatschinskyFeb 1, 1996; 45:223-241Banting Lecture 1995 Full Article
cos The Effect of Insulin on the Disposal of Intravenous Glucose: Results from Indirect Calorimetry and Hepatic and Femoral Venous Catheterization By diabetes.diabetesjournals.org Published On :: 1981-12-01 R A DeFronzoDec 1, 1981; 30:1000-1007Original Contribution Full Article
cos Evidence for 5'AMP-Activated Protein Kinase Mediation of the Effect of Muscle Contraction on Glucose Transport By diabetes.diabetesjournals.org Published On :: 1998-08-01 Tatsuya HayashiAug 1, 1998; 47:1369-1373Rapid Publications Full Article
cos High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells By diabetes.diabetesjournals.org Published On :: 2000-11-01 T InoguchiNov 1, 2000; 49:1939-1945Articles Full Article
cos Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats By diabetes.diabetesjournals.org Published On :: 1999-12-01 G XuDec 1, 1999; 48:2270-2276Articles Full Article
cos Triggering and amplifying pathways of regulation of insulin secretion by glucose By diabetes.diabetesjournals.org Published On :: 2000-11-01 JC HenquinNov 1, 2000; 49:1751-1760Articles Full Article
cos Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion By diabetes.diabetesjournals.org Published On :: 2000-03-01 HE HohmeierMar 1, 2000; 49:424-430Articles Full Article
cos Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance By diabetes.diabetesjournals.org Published On :: 1979-12-01 National Diabetes Data GroupDec 1, 1979; 28:1039-1057Articles Full Article
cos Thousands more patients with type 1 diabetes are getting flash glucose devices, data show By feeds.bmj.com Published On :: Monday, October 7, 2019 - 12:46 Full Article
cos Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes By diabetes.diabetesjournals.org Published On :: 2020-01-20T12:00:25-08:00 Incretin hormone dysregulation contributes to reduced insulin secretion and hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Resistance to glucose-dependent insulinotropic polypeptide (GIP) action may occur through desensitization or downregulation of β-cell GIP receptors (GIP-R). Studies in rodents and cell lines show GIP-R expression can be regulated through peroxisome proliferator–activated receptor (PPAR) response elements (PPREs). Whether this occurs in humans is unknown. To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-mediated insulin secretion and adipocyte GIP-R expression in subjects with well-controlled T2DM. Insulin sensitivity improved, but the insulinotropic effect of infused GIP was unchanged following 12 weeks of pioglitazone treatment. In parallel, we observed increased GIP-R mRNA expression in subcutaneous abdominal adipocytes from subjects treated with pioglitazone. Treatment of cultured human adipocytes with troglitazone increased PPAR binding to GIP-R PPREs. These results show PPAR agonists regulate GIP-R expression through PPREs in human adipocytes, but suggest this mechanism is not important for regulation of the insulinotropic effect of GIP in subjects with T2DM. Because GIP has antilipolytic and lipogenic effects in adipocytes, the increased GIP-R expression may mediate accretion of fat in patients with T2DM treated with PPAR agonists. Full Article
cos Mitochondrial Proton Leak Regulated by Cyclophilin D Elevates Insulin Secretion in Islets at Nonstimulatory Glucose Levels By diabetes.diabetesjournals.org Published On :: 2020-01-20T12:00:25-08:00 Fasting hyperinsulinemia precedes the development of type 2 diabetes. However, it is unclear whether fasting insulin hypersecretion is a primary driver of insulin resistance or a consequence of the progressive increase in fasting glycemia induced by insulin resistance in the prediabetic state. Herein, we have discovered a mechanism that specifically regulates non–glucose-stimulated insulin secretion (NGSIS) in pancreatic islets that is activated by nonesterified free fatty acids, the major fuel used by β-cells during fasting. We show that the mitochondrial permeability transition pore regulator cyclophilin D (CypD) promotes NGSIS, but not glucose-stimulated insulin secretion, by increasing mitochondrial proton leak. Islets from prediabetic obese mice show significantly higher CypD-dependent proton leak and NGSIS compared with lean mice. Proton leak–mediated NGSIS is conserved in human islets and is stimulated by exposure to nonesterified free fatty acids at concentrations observed in obese subjects. Mechanistically, proton leak activates islet NGSIS independently of mitochondrial ATP synthesis but ultimately requires closure of the KATP channel. In summary, we have described a novel nonesterified free fatty acid–stimulated pathway that selectively drives pancreatic islet NGSIS, which may be therapeutically exploited as an alternative way to halt fasting hyperinsulinemia and the progression of type 2 diabetes. Full Article
cos Perivascular Adipose Tissue Controls Insulin-Stimulated Perfusion, Mitochondrial Protein Expression, and Glucose Uptake in Muscle Through Adipomuscular Arterioles By diabetes.diabetesjournals.org Published On :: 2020-03-20T11:50:28-07:00 Insulin-mediated microvascular recruitment (IMVR) regulates delivery of insulin and glucose to insulin-sensitive tissues. We have previously proposed that perivascular adipose tissue (PVAT) controls vascular function through outside-to-inside communication and through vessel-to-vessel, or "vasocrine," signaling. However, direct experimental evidence supporting a role of local PVAT in regulating IMVR and insulin sensitivity in vivo is lacking. Here, we studied muscles with and without PVAT in mice using combined contrast-enhanced ultrasonography and intravital microscopy to measure IMVR and gracilis artery diameter at baseline and during the hyperinsulinemic-euglycemic clamp. We show, using microsurgical removal of PVAT from the muscle microcirculation, that local PVAT depots regulate insulin-stimulated muscle perfusion and glucose uptake in vivo. We discovered direct microvascular connections between PVAT and the distal muscle microcirculation, or adipomuscular arterioles, the removal of which abolished IMVR. Local removal of intramuscular PVAT altered protein clusters in the connected muscle, including upregulation of a cluster featuring Hsp90ab1 and Hsp70 and downregulation of a cluster of mitochondrial protein components of complexes III, IV, and V. These data highlight the importance of PVAT in vascular and metabolic physiology and are likely relevant for obesity and diabetes. Full Article
cos Human conflict and ecosystem services: finding the environmental price of warfare By feedproxy.google.com Published On :: Wed, 02 Jul 2014 10:57:18 +0000 2 July 2014 , Volume 90, Number 4 Robert A. Francis and Krishna Krishnamurthy Full Article
cos Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays By diabetes.diabetesjournals.org Published On :: 2019-09-20T12:00:23-07:00 Continuous glucose monitor (CGM) readings are delayed relative to blood glucose, and this delay is usually attributed to the latency of interstitial glucose levels. However, CGM-independent data suggest rapid equilibration of interstitial glucose. This study sought to determine the loci of CGM delays. Electrical current was measured directly from CGM electrodes to define sensor kinetics in the absence of smoothing algorithms. CGMs were implanted in mice, and sensor versus blood glucose responses were measured after an intravenous glucose challenge. Dispersion of a fluorescent glucose analog (2-NBDG) into the CGM microenvironment was observed in vivo using intravital microscopy. Tissue deposited on the sensor and nonimplanted subcutaneous adipose tissue was then collected for histological analysis. The time to half-maximum CGM response in vitro was 35 ± 2 s. In vivo, CGMs took 24 ± 7 min to reach maximum current versus 2 ± 1 min to maximum blood glucose (P = 0.0017). 2-NBDG took 21 ± 7 min to reach maximum fluorescence at the sensor versus 6 ± 6 min in adipose tissue (P = 0.0011). Collagen content was closely correlated with 2-NBDG latency (R = 0.96, P = 0.0004). Diffusion of glucose into the tissue deposited on a CGM is substantially delayed relative to interstitial fluid. A CGM that resists fibrous encapsulation would better approximate real-time deviations in blood glucose. Full Article
cos Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study By feeds.bmj.com Published On :: Wednesday, April 29, 2020 - 22:30 Full Article
cos Doctors as Taxi Drivers: The Costs of Brain Waste among Highly Skilled Immigrants in the United States By www.migrationpolicy.org Published On :: Mon, 21 Nov 2016 12:31:37 -0500 A report release and presentation of first-ever U.S. estimates on the actual economic costs of skill underutilization for immigrants, their families, and the U.S. economy, in terms of forgone earnings and unrealized federal, state, and local taxes. Full Article
cos Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease--A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE Dysglycemia, in this survey defined as impaired glucose tolerance (IGT) or type 2 diabetes, is common in patients with coronary artery disease (CAD) and associated with an unfavorable prognosis. This European survey investigated dysglycemia screening and risk factor management of patients with CAD in relation to standards of European guidelines for cardiovascular subjects. RESEARCH DESIGN AND METHODS The European Society of Cardiology’s European Observational Research Programme (ESC EORP) European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V (2016–2017) included 8,261 CAD patients, aged 18–80 years, from 27 countries. If the glycemic state was unknown, patients underwent an oral glucose tolerance test (OGTT) and measurement of glycated hemoglobin A1c. Lifestyle, risk factors, and pharmacological management were investigated. RESULTS A total of 2,452 patients (29.7%) had known diabetes. OGTT was performed in 4,440 patients with unknown glycemic state, of whom 41.1% were dysglycemic. Without the OGTT, 30% of patients with type 2 diabetes and 70% of those with IGT would not have been detected. The presence of dysglycemia almost doubled from that self-reported to the true proportion after screening. Only approximately one-third of all coronary patients had completely normal glucose metabolism. Of patients with known diabetes, 31% had been advised to attend a diabetes clinic, and only 24% attended. Only 58% of dysglycemic patients were prescribed all cardioprotective drugs, and use of sodium–glucose cotransporter 2 inhibitors (3%) or glucagon-like peptide 1 receptor agonists (1%) was small. CONCLUSIONS Urgent action is required for both screening and management of patients with CAD and dysglycemia, in the expectation of a substantial reduction in risk of further cardiovascular events and in complications of diabetes, as well as longer life expectancy. Full Article
cos Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE Glucosamine is a widely used supplement typically taken for osteoarthritis and joint pain. Emerging evidence suggests potential links of glucosamine with glucose metabolism, inflammation, and cardiometabolic risk. We prospectively analyzed the association of habitual glucosamine use with risk of type 2 diabetes (T2D) and assessed whether genetic susceptibility and inflammation status might modify the association. RESEARCH DESIGN AND METHODS This study analyzed 404,508 participants from the UK Biobank who were free of diabetes, cancer, or cardiovascular disease at baseline and completed the questionnaire on supplement use. Cox proportional hazards models were used to evaluate the association between habitual use of glucosamine and risk of incident T2D. RESULTS During a median of 8.1 years of follow-up, 7,228 incident cases of T2D were documented. Glucosamine use was associated with a significantly lower risk of T2D (hazard ratio 0.83, 95% CI 0.78–0.89) after adjustment for age, sex, BMI, race, center, Townsend deprivation index, lifestyle factors, history of disease, and other supplement use. This inverse association was more pronounced in participants with a higher blood level of baseline C-reactive protein than in those with a lower level of this inflammation marker (P-interaction = 0.02). A genetic risk score for T2D did not modify this association (P-interaction = 0.99). CONCLUSIONS Our findings indicate that glucosamine use is associated with a lower risk of incident T2D. Full Article
cos Former Denver Broncos QB Joe Flacco underwent neck surgery By www.upi.com Published On :: Thu, 07 May 2020 22:48:53 -0400 Former Denver Broncos quarterback Joe Flacco, who remains a free agent, could miss the start of the 2020 season after he underwent neck surgery. Full Article
cos Smartphone-Based Glucose Monitors and Applications in the Management of Diabetes: An Overview of 10 Salient "Apps" and a Novel Smartphone-Connected Blood Glucose Monitor By clinical.diabetesjournals.org Published On :: 2012-10-01 Joseph TranOct 1, 2012; 30:173-178Practical Pointers Full Article
cos How Foods Affect Blood Glucose: Glycemic Impact By clinical.diabetesjournals.org Published On :: 2011-10-01 Oct 1, 2011; 29:161-161Patient Information Full Article
cos Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works By clinical.diabetesjournals.org Published On :: 2003-10-01 Melpomeni PeppaOct 1, 2003; 21:Council's Voice Full Article
cos Treatment of Onychomycosis in Diabetic Patients By clinical.diabetesjournals.org Published On :: 2006-10-01 Jason A. WinstonOct 1, 2006; 24:160-166Feature Articles Full Article
cos Self-Monitoring of Blood Glucose: The Basics By clinical.diabetesjournals.org Published On :: 2002-01-01 Evan M. BenjaminJan 1, 2002; 20:Practical Pointers Full Article
cos Hypoglycemia? Low Blood Glucose? Low Blood Sugar? By clinical.diabetesjournals.org Published On :: 2012-01-01 Jan 1, 2012; 30:38-38Patient Information Full Article
cos Good to Know: Factors Affecting Blood Glucose By clinical.diabetesjournals.org Published On :: 2018-04-01 Apr 1, 2018; 36:202-202Patient Education Full Article
cos Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS Medical resource use data and responses to the EuroQol 5-Dimension (EQ-5D) instrument were collected at baseline and throughout the trial. Medical resources and medications were assigned values by using U.S. Medicare payments and wholesale acquisition costs, respectively. Secondary analyses used English costs. RESULTS Patients were followed for an average of 3.3 years, during which time those randomized to EQW experienced 0.41 fewer inpatient days (7.05 vs. 7.46 days; relative rate ratio 0.91; P = 0.05). Rates of outpatient medical visits were similar, as were total inpatient and outpatient costs. Mean costs for nonstudy diabetes medications over the study period were ~$1,600 lower with EQW than with placebo (P = 0.01). Total within-study costs, excluding study medication, were lower in the EQW arm than in the placebo arm ($28,907 vs. $30,914; P ≤ 0.01). When including the estimated cost of EQW, total mean costs were significantly higher in the EQW group than in the placebo group ($42,697 vs. $30,914; P < 0.01). With English costs applied, mean total costs, including exenatide costs, were £1,670 higher in the EQW group than the placebo group (£10,874 vs. £9,204; P < 0.01). There were no significant differences in EQ-5D health utilities between arms over time. CONCLUSIONS Medical costs were lower in the EQW arm than the placebo arm, but total costs were significantly higher once the cost of branded exenatide was incorporated. Full Article
cos Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Previous randomized trials found that treating periodontitis improved glycemic control in patients with type 2 diabetes (T2D), thus lowering the risks of developing T2D-related microvascular diseases and cardiovascular disease (CVD). Some payers in the U.S. have started covering nonsurgical periodontal treatment for those with chronic conditions, such as diabetes. We sought to identify the cost-effectiveness of expanding periodontal treatment coverage among patients with T2D. RESEARCH DESIGN AND METHODS A cost-effectiveness analysis was conducted to estimate lifetime costs and health gains using a stochastic microsimulation model of oral health conditions, T2D, T2D-related microvascular diseases, and CVD of the U.S. population. Model parameters were obtained from the nationally representative National Health and Nutrition Examination Survey (NHANES) (2009–2014) and randomized trials of periodontal treatment among patients with T2D. RESULTS Expanding periodontal treatment coverage among patients with T2D and periodontitis would be expected to avert tooth loss by 34.1% (95% CI –39.9, –26.5) and microvascular diseases by 20.5% (95% CI –31.2, –9.1), 17.7% (95% CI –32.7, –4.7), and 18.4% (95% CI –34.5, –3.5) for nephropathy, neuropathy, and retinopathy, respectively. Providing periodontal treatment to the target population would be cost saving from a health care perspective at a total net savings of $5,904 (95% CI –6,039, –5,769) with an estimated gain of 0.6 quality-adjusted life years per capita (95% CI 0.5, 0.6). CONCLUSIONS Providing nonsurgical periodontal treatment to patients with T2D and periodontitis would be expected to significantly reduce tooth loss and T2D-related microvascular diseases via improved glycemic control. Encouraging patients with T2D and poor oral health conditions to receive periodontal treatment would improve health outcomes and still be cost saving or cost-effective. Full Article
cos The Association Between Poor Glycemic Control and Health Care Costs in People With Diabetes: A Population-Based Study By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To analyze the differences in health care costs according to glycemic control in people with type 2 diabetes. RESEARCH DESIGN AND METHODS Data on health care resource utilization from 100,391 people with type 2 diabetes were extracted from the electronic database used at the Catalan Health Institute. Multivariate regression models were carried out to test the impact of glycemic control (HbA1c) on total health care, hospital admission, and medication costs; model 1 adjusted for a variety of covariates, and model 2 also included micro- and macrovascular complications. Glycemic control was classified as good for HbA1c <7%, fair for ≥7% to <8%, poor for ≥8% to <10%, and very poor for ≥10%. RESULTS Mean per patient annual direct medical costs were 3,039 ± SD 6,581. Worse glycemic control was associated with higher total health care costs: compared with good glycemic control, health care costs increased by 18% (509.82) and 23% (661.35) in patients with very poor and poor glycemic control, respectively, when unadjusted and by 428.3 and 395.1, respectively, in model 2. Medication costs increased by 12% in patients with fair control and by 28% in those with very poor control (model 2). Patients with poor control had a higher probability of hospitalization than those with good control (5% in model 2) and a greater average cost when hospitalization occurred (811). CONCLUSIONS Poor glycemic control was directly related to higher total health care, hospitalization, and medication costs. Preventive strategies and good glycemic control in people with type 2 diabetes could reduce the economic impact associated with this disease. Full Article
cos Impact of a Telephonic Intervention to Improve Diabetes Control on Health Care Utilization and Cost for Adults in South Bronx, New York By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE Self-management education and support are essential for improved diabetes control. A 1-year randomized telephonic diabetes self-management intervention (Bronx A1C) among a predominantly Latino and African American population in New York City was found effective in improving blood glucose control. To further those findings, this current study assessed the intervention’s impact in reducing health care utilization and costs over 4 years. RESEARCH DESIGN AND METHODS We measured inpatient (n = 816) health care utilization for Bronx A1C participants using an administrative data set containing all hospital discharges for New York State from 2006 to 2014. Multilevel mixed modeling was used to assess changes in health care utilization and costs between the telephonic diabetes intervention (Tele/Pr) arm and print-only (PrO) control arm. RESULTS During follow-up, excess relative reductions in all-cause hospitalizations for the Tele/Pr arm compared with PrO arm were statistically significant for odds of hospital use (odds ratio [OR] 0.89; 95% CI 0.82, 0.97; P < 0.01), number of hospital stays (rate ratio [RR] 0.90; 95% CI 0.81, 0.99; P = 0.04), and hospital costs (RR 0.90; 95% CI 0.84, 0.98; P = 0.01). Reductions in hospital use and costs were even stronger for diabetes-related hospitalizations. These outcomes were not significantly related to changes observed in hemoglobin A1c during individuals’ participation in the 1-year intervention. CONCLUSIONS These results indicate that the impact of the Bronx A1C intervention was not just on short-term improvements in glycemic control but also on long-term health care utilization. This finding is important because it suggests the benefits of the intervention were long-lasting with the potential to not only reduce hospitalizations but also to lower hospital-associated costs. Full Article
cos New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2) By care.diabetesjournals.org Published On :: 2014-12-01 Hannele Yki-JärvinenDec 1, 2014; 37:3235-3243Emerging Technologies and Therapeutics Full Article
cos Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON By care.diabetesjournals.org Published On :: 2016-05-01 Muh Geot WongMay 1, 2016; 39:694-700Cardiovascular Disease and Diabetes Full Article
cos Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2013-10-01 Ralph A. DeFronzoOct 1, 2013; 36:3169-3176Emerging Technologies and Therapeutics Full Article
cos Vitamin E Reduction of Protein Glycosylation in Diabetes: New Prospect for Prevention of Diabetic Complications? By care.diabetesjournals.org Published On :: 1991-01-01 Antonio CerielloJan 1, 1991; 14:68-72Short Report Full Article
cos Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range By care.diabetesjournals.org Published On :: 2019-08-01 Tadej BattelinoAug 1, 2019; 42:1593-1603International Consensus Report Full Article
cos Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes By care.diabetesjournals.org Published On :: 2015-12-01 Robert R. HenryDec 1, 2015; 38:2258-2265Special Article Collection: Insulin Full Article
cos New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) By care.diabetesjournals.org Published On :: 2014-10-01 Matthew C. RiddleOct 1, 2014; 37:2755-2762Emerging Technologies and Therapeutics Full Article
cos A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves By care.diabetesjournals.org Published On :: 1994-02-01 Mary M TaiFeb 1, 1994; 17:152-154Short Report Full Article
cos Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial By care.diabetesjournals.org Published On :: 2014-05-01 Bruce A. PerkinsMay 1, 2014; 37:1480-1483Novel Communications in Diabetes Full Article
cos Relationship Between {beta}-Cell Mass and Fasting Blood Glucose Concentration in Humans By care.diabetesjournals.org Published On :: 2006-03-01 Robert A. RitzelMar 1, 2006; 29:717-718BR Pathophysiology/Complications Full Article
cos Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women By care.diabetesjournals.org Published On :: 1993-10-01 Dario GiuglianoOct 1, 1993; 16:1387-1390Short Report Full Article
cos Improved Glycemic Control in Poorly Controlled Patients with Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring By care.diabetesjournals.org Published On :: 2006-12-01 Dorothee DeissDec 1, 2006; 29:2730-2732BR Emerging Treatments and Technologies Full Article
cos Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland By care.diabetesjournals.org Published On :: 1979-03-01 Kalevi PyöräläMar 1, 1979; 2:131-141Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications Full Article
cos Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations By care.diabetesjournals.org Published On :: 1979-03-01 T A WelbornMar 1, 1979; 2:154-160Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications Full Article
cos Economic Costs of Diabetes in the U.S. in 2017 By care.diabetesjournals.org Published On :: 2018-05-01 American Diabetes AssociationMay 1, 2018; 41:917-928The Costs Of Diabetes Full Article
cos Prevalence and Determinants of Glucose Intolerance in a Dutch Caucasian Population: The Hoorn Study By care.diabetesjournals.org Published On :: 1995-09-01 Johanna M MooySep 1, 1995; 18:1270-1273Short Report Full Article
cos International Consensus on Use of Continuous Glucose Monitoring By care.diabetesjournals.org Published On :: 2017-12-01 Thomas DanneDec 1, 2017; 40:1631-1640Continuous Glucose Monitoring and Risk of Hypoglycemia Full Article
